Cotreatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 350-357

  Nimmanapalli, Ramadevi ^a   Porosnicu, Mercedes ^b   Nguyen, Diep ^b   Worthington, Elizabeth ^b   O’Bryan, Erica ^a   Perkins, Charles ^b   Bhalla, Kapil ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CASPASE 3; CASPASE 9; IMATINIB; PROTEIN P120; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CYTOCHROME C GROUP; DRUG COMBINATIONS; DRUG SYNERGISM; GENES, ABL; HUMANS; LEUKEMIA; LIGANDS; MEMBRANE GLYCOPROTEINS; PIPERAZINES; PYRIMIDINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035126944     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Death receptors: Signaling and modulation
2. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
3. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
4. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
5. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
6. Caspases. Intracellular signaling by proteolysis
7. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
8. Caspase activation: The induced-proximity model
9. Bid, a Bc12 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
10. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
11. Lprevents this release but not tumor necrosis factor-R1/Fas death
12. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade
13. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
14. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis
15. Apoptotic pathways: The roads to ruin
16. The role of Apaf-1, Caspase-9, and Bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis
17. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
18. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
19. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/INFRl-induced apoptosis
20. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
21. X-linked IAP is a direct inhibitor of cell-death proteases
22. IAP-Family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95): Bax, caspases, and anticancer drugs
23. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
24. Chronic myelogenous leukemia: Biology and therapy
25. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
26. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
27. sinduces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis
28. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
29. BCR-ABLactivates p65 NF-κB)
30. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
31. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway
32. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
33. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
34. In vitro eradication of human Bcr/Abl-positive leukemia cells with an ABL kinase inhibitor
35. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
36. Bcl-xL overexpression inhibits Taxol-induced Yama protease activity and apoptosis
37. L
38. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
39. I-β-D-Arabinofuranosylcytosine-, mitoxantrone- and paclitaxel-induced apoptosis in HL-60 cells: Improved method for detection of internucleosomal DNA fragmentation
40. Molecular determinants of additive apoptotic effects of chemotherapeutic agents and TRAIL (Apo2L)
41. Suicidal tendencies: Apoptotic cell death by caspase family proteinases
42. Differential requirements for caspase 9 in apoptotic pathways in vivo
43. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
44. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
45. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
46. Linhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis
47. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases
48. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90
49. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation
50. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
51. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
52. Induction of resistance to the Abelson inhibitor STI-571 in human leukemic cells through gene amplification
53. Mechanism of resistance to the ABL tyrosine kinase inhibitor STl-571 in BCR/ABL-transformed hematopoietic cell lines
54. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
55. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides
56. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment
57. 3enhances selective cytotoxic effects of STI-571 against Bcr-Abl positive acute leukemia cells
58. Effects of bcr-abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
59. Oncogene inactivation in a mouse model